GURU.Markets stock price, segment price, and overall market index valuation
The company's share price COSCIENS Biopharma Inc.
The value of COSCIENS, a privately held biopharmaceutical company, is determined by its progress in drug development. The potential share price will depend on the results of clinical trials and the commercial potential of its developments.
Share prices of companies in the market segment - Specialized pharma
COSCIENS Biopharma is a biopharmaceutical company developing specialized drugs for the treatment of various diseases. We've classified it as a "Specialty Pharma" company, and the chart below shows how investors value companies operating in niche medical fields.
Broad Market Index - GURU.Markets
COSCIENS is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of various diseases. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the industry's prospects.
Change in the price of a company, segment, and market as a whole per day
CSCI - Daily change in the company's share price COSCIENS Biopharma Inc.
For COSCIENS Biopharma Inc., daily volatility reflects sensitivity to scientific data and progress in the development of its drugs. This metric is an important element in formulas assessing risks and potential in biotech.
Daily change in the price of a set of shares in a market segment - Specialized pharma
COSCIENS Biopharma is a biopharmaceutical company developing drugs for the treatment of various diseases. The biotech sector is known for its high volatility. The chart below shows the average daily fluctuations in this industry, allowing one to assess how the CSCI's dynamics correspond to overall trends.
Daily change in the price of a broad market stock, index - GURU.Markets
COSCIENS Biopharma is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization COSCIENS Biopharma Inc.
For COSCIENS Biopharma Inc., year-over-year performance is a story of developing drugs for rare diseases. Its 12-month market capitalization depends entirely on progress in preclinical and clinical trials. Every successful step confirms the potential of its scientific platform and brings the development of new drugs closer.
Annual dynamics of market capitalization of the market segment - Specialized pharma
As a private biopharmaceutical company, COSCIENS likely specializes in niche drugs. Its growth depends on the successful commercialization of its products and R&D results. Its valuation dynamics will reflect its success in this area, potentially outperforming the sector due to its flexibility and specialization.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
COSCIENS Biopharma, a pharmaceutical company focused on specialized drugs, likely operates in a niche market. Its annual market capitalization dynamics relative to the market will likely be determined by progress in its R&D programs rather than general economic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization COSCIENS Biopharma Inc.
Operating in the pharmaceutical sector, COSCIENS exhibits the dynamics typical of biotech: it depends on progress in its scientific research and clinical programs. News of trial results are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
COSCIENS Biopharma Inc. is a biopharmaceutical company focused on developing specialized drugs. Its sector dynamics, shown in the chart, reflect the high risks and potential of biotech. Against this backdrop, it is possible to assess how its research and development pipeline is progressing through clinical trials to address unmet medical needs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
COSCIENS Biopharma is a biotech company whose shares are preoccupied with the results of clinical trials. Their monthly performance is completely disconnected from the market and is driven by drug development news. The chart clearly illustrates that for such companies, trial data is more important than the overall economic situation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization COSCIENS Biopharma Inc.
COSCIENS Biopharma, a pharmaceutical company whose weekly stock price reflects progress in its drug development. News about clinical trials, partnerships, and regulatory decisions drive the highly volatile short-term trends typical of the biotech sector.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
COSCIENS Biopharma and the entire early-stage biotech sector are driven by a common backdrop of investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how a company's shares react to this shared "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
COSCIENS Biopharma is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that the CSCI's dynamics have little correlation with the market.
Market capitalization of the company, segment and market as a whole
CSCI - Market capitalization of the company COSCIENS Biopharma Inc.
The COSCIENS Biopharma chart is a financial bet on the development and commercialization of specialty pharmaceuticals. This company's chart shows how the market evaluates its product portfolio, scientific developments, and ability to carve out a niche in the competitive pharmaceutical market by solving specific medical problems.
CSCI - Share of the company's market capitalization COSCIENS Biopharma Inc. within the market segment - Specialized pharma
COSCIENS Biopharma is a company focused on developing specialized pharmaceutical products. Its market capitalization in the biotech sector reflects its status as a highly specialized player. The company's market weight reflects the market's assessment of the potential of its developments in specific therapeutic niches.
Market capitalization of the market segment - Specialized pharma
COSCIENS Biopharma is a biotechnology company focused on developing specialized drugs. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which the company is trying to find its unique niche.
Market capitalization of all companies included in a broad market index - GURU.Markets
COSCIENS Biopharma is a clinical-stage biopharmaceutical company. Its market capitalization represents a financial bet on a scientific breakthrough. Its volatile value relative to the market reflects all the risks and hopes associated with the lengthy and expensive process of developing new drugs.
Book value capitalization of the company, segment and market as a whole
CSCI - Book value capitalization of the company COSCIENS Biopharma Inc.
COSCIENS Biopharma is an early-stage company. Its book value is primarily derived from cash raised for R&D. The chart below shows how this capital is spent on developing new drugs. This is a visualization of its financial "running headroom."
CSCI - Share of the company's book capitalization COSCIENS Biopharma Inc. within the market segment - Specialized pharma
COSCIENS Biopharma is a biopharmaceutical company. Its core capital is intellectual property, tied to its drugs. The share of physical assets will be minimal, reflecting a focus on research rather than ownership of large manufacturing facilities.
Market segment balance sheet capitalization - Specialized pharma
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, COSCIENS, as a company focused on developing specialized drugs, appears "light." Its value lies in its scientific platform and patents, not in its large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
COSCIENS Biopharma is a biopharmaceutical company. Its assets are not factories, but intellectual property: patents for potential drugs and research data. The company's balance sheet is the value of scientific research, which may one day lead to the creation of a real drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - COSCIENS Biopharma Inc.
COSCIENS's balance sheet is its scientific research. Its market capitalization is its bet on its success. The MvsBCap_Co chart shows how many times the "hope" for a new drug is worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Specialized pharma
COSCIENS Biopharma is a biopharmaceutical company focused on developing specialized drugs. This chart shows the speculative market valuation of its research portfolio and potential to bring new drugs to market in its therapeutic niche.
Market to book capitalization ratio for the market as a whole
COSCIENS Biopharma is a pharmaceutical company focused on specialized drugs. As with other biotech companies, investors primarily evaluate the potential of its scientific developments. This metric reflects the premium the market is willing to pay for the hope of a successful new drug, even if the company's tangible assets are small.
Debts of the company, segment and market as a whole
CSCI - Company debts COSCIENS Biopharma Inc.
CSCI is the ticker symbol for COSCIENS Biopharma. As a biopharmaceutical company, it uses capital to fund the development of its drugs. This chart would reflect raising funds, likely equity, at an early stage to conduct preclinical and clinical trials, a long, capital-intensive, and high-risk process.
Market segment debts - Specialized pharma
COSCIENS Biopharma is likely an early-stage biotech company. At this stage, companies rely entirely on venture capital or grants to fund their research. A company's chart typically shows its cash burn rate, not its debt, which is a key indicator of its financial health.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio COSCIENS Biopharma Inc.
COSCIENS Biopharma is an early-stage biopharmaceutical company. Its financial future depends entirely on the success of its scientific developments. This chart shows its reliance on external financing. For a company without revenue, any debt is a huge risk and a bet that its research will ultimately lead to a drug.
Market segment debt to market segment book capitalization - Specialized pharma
COSCIENS Biopharma is likely a small biopharmaceutical company. Drug development is a long, risky, and capital-intensive process. The chart shows how the debt load of this small company, which finances R&D, compares to the overall market capitalization and financial strength of pharmaceutical giants.
Debt to book value of all companies in the market
COSCIENS Biopharma (CSCI) is a biopharmaceutical company focused on developing specialized drugs. Being in the research stage, the company has no revenue. This chart shows the overall market leverage. It serves as a contrast, emphasizing that CSCI's future depends on the success of investor-funded R&D, not debt.
P/E of the company, segment and market as a whole
P/E - COSCIENS Biopharma Inc.
This chart for COSCIENS Biopharma, likely an early-stage biotech, will reflect investors' faith in its scientific developments. There will be no P/E ratio. The company's valuation will be based solely on the potential of its drug candidates, and the chart's dynamics will depend entirely on news about clinical trials.
P/E of the market segment - Specialized pharma
This is the average P/E for biotech companies. For COSCIENS Biopharma, an early-stage company, it serves as a benchmark. It reflects the overall level of investor confidence in the sector, providing context for COSCIENS's valuation, which is a bet on its unique scientific approach and pipeline of candidates.
P/E of the market as a whole
COSCIENS Biopharma is a biopharmaceutical company focused on developing drugs for the treatment of specialized diseases. Its valuation, like that of many early-stage companies, is based on the potential of its scientific developments. This chart shows the mood in the biotech sector. It helps understand how the overall investment climate in the sector affects a company's ability to fund its research and development.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company COSCIENS Biopharma Inc.
COSCIENS Biopharma is likely a small biotech company. For such an early-stage company, this chart reflects analysts' speculative expectations. It is based not on current revenue, but on an assessment of the scientific potential of its developments and the likelihood of future success in clinical trials and subsequent commercialization.
%20P%2FE%20COSCIENS%20Biopharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-COSCIENS-Biopharma-Inc.&v=1772578703459 "Chart of the company's future (projected) P/E COSCIENS Biopharma Inc.")
Future (projected) P/E of the market segment - Specialized pharma
COSCIENS Biopharma Inc. is a pharmaceutical company specializing in the development and commercialization of specialty drugs. This chart shows average expectations for the pharmaceutical sector. The CSCI's position may indicate how investors view its product portfolio, its acquisition strategy, and its market position.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772578703494 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
COSCIENS Biopharma is a biotechnology company focused on developing specialized pharmaceuticals. Its value depends on its success in research and development. Overall market sentiment, visible in this chart, influences the availability of capital for R&D.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772578703515 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc. is a biopharmaceutical company focused on drug development. This timeline, like many biotech companies, will reflect the path from a scientific idea to a potential product. Loss-making phases are associated with high R&D costs, while future profitability depends entirely on success in clinical trials and commercialization.
Profit of companies in the market segment - Specialized pharma
COSCIENS Biopharma Inc. is a pharmaceutical company focused on developing specialized drugs. Profitability in this sector, as this chart shows, depends on the ability to find and occupy a niche. For CSCI, this could be developing drugs for rare diseases or creating improved versions of existing drugs with fewer side effects.
Overall market profit
COSCIENS Biopharma, a pharmaceutical company focused on developing specialized drugs, operates in a field where success is determined by scientific innovation. Demand for its medications is independent of the economic situation, as this chart shows. The company's key drivers are clinical trial results and regulatory approval.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company COSCIENS Biopharma Inc.
COSCIENS Biopharma is a pharmaceutical company focused on developing specialized drugs. This chart reflects analyst expectations for its future earnings, which depend on the success of its research, clinical trials, and product launches.
%20profit%20of%20the%20company%20COSCIENS%20Biopharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-COSCIENS-Biopharma-Inc.&v=1772578703579 "Graph of future (projected) profit of the company COSCIENS Biopharma Inc.")
Future (predicted) profit of companies in the market segment - Specialized pharma
COSCIENS Biopharma Inc. is a biotechnology company likely focused on developing specialized pharmaceuticals. The success of such companies depends on scientific innovation and clinical trial results. This chart shows the profit forecast for the pharmaceutical sector, providing a general framework for assessing the prospects of its niche developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772578703677 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
COSCIENS Biopharma is an early-stage biopharmaceutical company. Its value is based on the future potential of its research and development, not on current revenue. The overall economic outlook, shown in the chart, influences its value through the availability of risk capital, which becomes scarce during periods of market pessimism.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772578703712 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - COSCIENS Biopharma Inc.
COSCIENS Biopharma is an early-stage biopharmaceutical company. Like many companies in this sector, it likely lacks significant commercial revenue. The chart reflects a speculative valuation by investors who are betting on the scientific potential of its developments rather than its current financial performance.
P/S market segment - Specialized pharma
COSCIENS Biopharma is a biotechnology company specializing in pharmaceutical product development. This chart shows the average revenue estimate for the biotech industry. It helps understand how investor expectations for its product line and scientific developments differ from the average for the innovative pharmaceutical industry.
P/S of the market as a whole
COSCIENS Biopharma Inc. is likely a biotech company focused on a specific therapeutic area. Its value is likely determined by the potential of its scientific developments rather than current revenue. The chart of average market valuations serves to illustrate the speculative nature of early-stage biotech investments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company COSCIENS Biopharma Inc.
COSCIENS Biopharma is a biotech company. The chart is a measure of investor optimism. It values the company based on the significant future revenue its therapy could generate if it successfully completes clinical trials and addresses existing medical needs.
%20P%2FS%20COSCIENS%20Biopharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-COSCIENS-Biopharma-Inc.&v=1772578703815 "The graph of the company's future (projected) P/S COSCIENS Biopharma Inc.")
Future (projected) P/S of the market segment - Specialized pharma
COSCIENS Biopharma Inc. is a biotechnology company specializing in pharmaceutical development. The data in the chart reflects average market expectations for future sales in the specialty pharmaceuticals sector. This allows investors to assess how they view the scientific potential and commercial prospects of COSCIENS's developments compared to other players.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772578703865 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
COSCIENS Biopharma is a biopharmaceutical company developing new drugs. Its future depends on the success of its scientific developments and clinical trials. This indicator of overall revenue expectations is of little significance to the company. CSCI's entire value lies in its intellectual property and the potential to create a breakthrough drug.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772578703890 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales COSCIENS Biopharma Inc.
COSCIENS Biopharma is a biopharmaceutical company developing specialized drugs. Being in the research stage, it typically does not have stable sales revenue. Any revenue shown in this chart likely comes from licensing agreements or research grants.
Sales of companies in the market segment - Specialized pharma
COSCIEN.S Biopharma Inc. is a biopharmaceutical company, likely in the early stages of development. These companies focus on scientific research to develop new drugs in specific therapeutic areas. This chart, showing total revenue in the sector, provides an overview of the overall investment climate and commercial potential in the pharmaceutical industry.
Overall market sales
COSCIENS Biopharma is a biopharmaceutical company developing specialized drugs. Its prospects depend on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company COSCIENS Biopharma Inc.
COSCIENS Biopharma is a pharmaceutical company specializing in the development and commercialization of niche drugs. Its future revenue depends on the market success of its products and progress in developing new ones. This chart reflects analyst growth expectations for the specialty pharmaceuticals segment.
%20sales%20of%20the%20company%20COSCIENS%20Biopharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-COSCIENS-Biopharma-Inc.&v=1772578703953 "Schedule of future (projected) sales of the company COSCIENS Biopharma Inc.")
Future (projected) sales of companies in the market segment - Specialized pharma
COSCIENS Biopharma is a biopharmaceutical company focused on the development and commercialization of specialty pharmaceuticals. Its success depends on clinical trial results and regulatory approvals. This chart shows projected revenue for the entire specialty pharmaceuticals segment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772578703970 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
COSCIENS Biopharma is an early-stage biotech company focused on developing new drugs. Its future depends entirely on the success of its scientific research and its ability to attract funding. This chart, reflecting overall investor sentiment, impacts the availability of capital for speculative biotech companies with very long horizons.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772578703979 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality COSCIENS Biopharma Inc.
COSCIENS Biopharma is a biopharmaceutical company focused on developing treatments for diseases. While in the research stage, it incurs significant research expenses. This chart illustrates the financial side of innovation: current expenses are an investment in the development of potentially profitable drugs.
Market segment marginality - Specialized pharma
COSCIENS Biopharma is a biopharmaceutical company focused on drug development. This chart shows the average revenue in the pharmaceutical industry. As an early-stage company, its future ability to exceed this figure will depend entirely on the success of its scientific development, progress through clinical trials, and subsequent commercialization.
Market marginality as a whole
COSCIENS Biopharma Inc. is a pharmaceutical company focused on developing specialized drugs. Its financial model is likely driven by research and development, which is typical for the biotech sector. This total revenue chart clearly demonstrates the gap between expensive research and development and the current profitability of established businesses.
Employees in the company, segment and market as a whole
Number of employees in the company COSCIENS Biopharma Inc.
COSCIENS Biopharma is a biopharmaceutical company focused on developing specialized drugs. While in the research stage, the company operates with a small and flexible team. This graph shows a compact scientific staff, typical for an organization whose core business is preclinical development.
Share of the company's employees COSCIENS Biopharma Inc. within the market segment - Specialized pharma
Brookfield Property Partners is one of the world's largest owners of commercial real estate, from office towers to shopping malls. Like many similar companies, its own staff is minimal. This chart clearly illustrates its business model: value is created by a portfolio of billions of dollars in assets, not by a large corporate team, as is typical for real estate owners.
Number of employees in the market segment - Specialized pharma
COSCIENS Biopharma Inc. is a biopharmaceutical company, likely in the early stages of development. Its personnel schedule will likely show a small and focused team of scientists. Minor staffing changes will reflect progress in preclinical research and efforts to secure funding to advance to clinical trials.
Number of employees in the market as a whole
COSCIENS Biopharma is an early-stage biotech company. Its minimal staffing schedule speaks volumes about its focus on science. The team consists of several key scientists advancing research. Any change here is a significant event, signaling progress in development or securing funding for the next stage.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company COSCIENS Biopharma Inc. (CSCI)
COSCIENS Biopharma is a biopharmaceutical company. Like most biotech companies in the research stage, its market value reflects not revenue, but the potential of its scientific developments. This chart shows how investors value the company's intellectual property (patents) per scientist working on new drugs.
%20of%20the%20company%20COSCIENS%20Biopharma%20Inc.%20(CSCI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-COSCIENS-Biopharma-Inc.-CSCI&v=1772578704149 "Chart of market capitalization per employee (in thousands of dollars) of the company COSCIENS Biopharma Inc. (CSCI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
COSCIENS Biopharma Inc. is a biotechnology company developing specialty pharmaceuticals. Its value is determined by its research and development potential and intellectual property. This chart shows how investors value its research portfolio based on the value of its small research team.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772578704170 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
COSCIENS Biopharma is a biopharmaceutical company focused on developing specialized drugs. This chart illustrates the assessment of scientific potential. For such a company, a high market capitalization per employee reflects investors' confidence in the development pipeline and the ability of a small team of scientists to create a marketable product.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772578704210 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company COSCIENS Biopharma Inc. (CSCI)
COSCIENS (formerly Cocrystal Pharma) is a biotech company that appears to be in the process of transformation or is a "shell." It was focused on antiviral drugs. This negative graph reflects R&D burnout or minimal administrative expenses.
%20Chart%20COSCIENS%20Biopharma%20Inc.%20(CSCI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-COSCIENS-Biopharma-Inc.-CSCI&v=1772578704236 "Company Profit Per Employee (in thousands of dollars) Chart COSCIENS Biopharma Inc. (CSCI)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
COSCIENS Biopharma is a biotech company, likely in the early stages of development. This chart shows the cash burn per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company is investing in its research programs to create new drugs compared to other biotech startups.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772578704277 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
COSCIENS Biopharma is a biotech R&D company focused on treating diseases of the central nervous system (CNS). The company has no commercial products and, therefore, no profit. This graph shows a negative value—the investment (loss) per scientist working in this complex field of medicine.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772578704295 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee COSCIENS Biopharma Inc. (CSCI)
COSCIENS Biopharma is a biopharmaceutical company. For a company in the research stage, this chart will reflect key monetization milestones. Increases in revenue per employee will likely result from a licensing agreement or partnership with a major pharmaceutical company to co-develop its drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-COSCIENS-Biopharma-Inc.-CSCI&v=1772578704301 "Sales chart per company employee COSCIENS Biopharma Inc. (CSCI)")
Sales per employee in the market segment - Specialized pharma
COSCIENS (CSCI) is an early-stage biotech company. The company likely has no approved products and, therefore, no commercial revenue. This chart doesn't reflect their value. Staff productivity here will be zero, as the entire staff is focused on R&D, not sales.
Sales per employee for the market as a whole
COSCIENS Biopharma is a biotech company. This figure is expectedly low at the R&D stage. The company invests in highly qualified scientists even before it has a commercial product on the market. This graph is an indicator of the future: it will show an explosive increase in efficacy if clinical trials are successful.
Short shares by company, segment and market as a whole
Shares shorted by company COSCIENS Biopharma Inc. (CSCI)
COSCIENS Biopharma (CSCI) is a biotech company focused on developing drugs for the treatment of central nervous system (CNS) diseases. This metric reflects a bearish bet. Bears are skeptical about the chances of success in the complex field of the CNS, where clinical trial failures are common.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-COSCIENS-Biopharma-Inc.-CSCI&v=1772578704398 "Short Shares Chart for the Company COSCIENS Biopharma Inc. (CSCI)")
Shares shorted by market segment - Specialized pharma
COSCIENS Biopharma is a biopharmaceutical company focused on developing treatments in psychiatry and neurology. This chart shows the overall bearish sentiment across the entire CNS (central nervous system) biotech sector. The surge in shorts in the sector reflects deep investor skepticism about new developments in this complex field.
Shares shorted by the overall market
COSCIENS Biopharma (CSCI) is in the clinical stage, its value lies in R&D, not revenue. Such companies are dependent on investors. This level of pessimism is critical, as periods of fear typically freeze capital markets, which are vital for the survival and research of speculative biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator COSCIENS Biopharma Inc. (CSCI)
COSCIENS Biopharma is a speculative biotech company. In stocks with such low liquidity and an unclear business, the "temperature" can change instantly. This indicator shows how rare news or rumors about R&D developments can trigger a sharp but short-lived "overheating" of interest, followed by a prolonged "cooling."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-COSCIENS-Biopharma-Inc.-CSCI&v=1772578704471 "RSI 14 indicator chart for the company's stock COSCIENS Biopharma Inc. (CSCI)")
RSI 14 Market Segment - Specialized pharma
COSCIENS Biopharma — *biotech*. The "Specialized Pharma" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is CSCI's growth due to their R&D or is *the entire* biotech sector simply overheated by expectations?
RSI 14 for the overall market
For COSCIENS Biopharma, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CSCI (COSCIENS Biopharma Inc.)
COSCIENS Biopharma is a biotechnology company developing specialty pharmaceuticals. This chart shows the average target price. Analysts' forecasts are based on an assessment of its R&D portfolio, the likelihood of success in clinical trials, and the potential market size for its developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CSCI-COSCIENS-Biopharma-Inc.&v=1772578704594 "A chart showing analyst consensus forecasts for the expected stock price. CSCI (COSCIENS Biopharma Inc.)")
The difference between the consensus estimate and the actual stock price CSCI (COSCIENS Biopharma Inc.)
COSCIENS is a biotech R&D company focused on developing drugs for rare diseases. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their "venture capital" assessment of the company's scientific portfolio and its chances of success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CSCI-COSCIENS-Biopharma-Inc.&v=1772578704613 "A chart showing the difference between the consensus forecast and the actual stock price. CSCI (COSCIENS Biopharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
COSCIENS Biopharma (CSCI) is an early-stage biotech company developing drugs to treat rare diseases. This chart shows analysts' overall expectations for the specialty pharmaceuticals sector. It reflects whether experts believe in new R&D breakthroughs or anticipate a "winter" in speculative biotech funding.
Analysts' consensus forecast for the overall market share price
COSCIENS Biopharma (CSCI) is a micro-cap clinical-stage biopharmaceutical company focused on cancer treatment. This high-risk research project is underway. This chart shows the overall market risk appetite and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index COSCIENS Biopharma Inc.
COSCIENS Biopharma is a biotech R&D company focused on rare (orphan) diseases. It's a binary risk business: all or nothing. This chart is a pure indicator of faith in their R&D. It doesn't reflect current sales (they don't have any), but rather a speculative assessment of their scientific progress, clinical trial data, and their chances of regulatory approval.
AKIMA Market Segment Index - Specialized pharma
COSCIENS Biopharma (CSCI) is a specialty pharmaceutical company. They focus on developing drugs for rare diseases where effective treatments are often lacking. This is niche R&D. This chart compares their composite index to the average for the specialty pharmaceutical sector.
The AKIM Index for the overall market
COSCIENS Biopharma (formerly Aeterna Zentaris) is a biopharmaceutical company formed by the merger of Aeterna and Ceapro. It is developing a portfolio in oncology and biocosmetics. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this rebranded company stacks up against overall economic trends.
